Saturday, July 11, 2026

Drug profile · INN

vidarabine

vidarabine (VIRA-A) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — vidarabine
US status
approved
Class
Route
OPHTHALMIC
Patents
0
Programs
0
Data quality
0.84

Quick answer

vidarabine (VIRA-A) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN vidarabine
Brand VIRA-A
Mechanism Human herpesvirus 1 DNA polymerase inhibitor
Target DNA polymerase catalytic subunit
Route OPHTHALMIC
Formulation INJECTABLE

Mechanism of action

Human herpesvirus 1 DNA polymerase inhibitor

Primary target: DNA polymerase catalytic subunit

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. famciclovir Human herpesvirus 1 DNA polymerase inhibitor
  4. foscarnet sodium Human herpesvirus 1 DNA polymerase inhibitor
  5. ganciclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  6. penciclovir Human herpesvirus 1 DNA polymerase inhibitor

Frequently asked questions

What is vidarabine?

vidarabine (VIRA-A) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for vidarabine?

VIRA-A is a marketed brand name for vidarabine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of vidarabine?

vidarabine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.